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Thus, we were able to calculate the
mean difference instead of the stan-
dardized mean difference of the param-
eters of interest (PAJV and AVA).
Although our results are similar to
those of the original meta-analysis,
even after including the SEAS study,
we have enclosed the correct method-
ology to arrive at the conclusion.
Deepak Vedamurthy, MD
Janos Molnar
Rohit Arora, MD
Chicago Medical School
Chicago, III
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TRANSCATHETER HEART
VALVE OPTIMAL SIZE
To the Editor:
We read with interest the comments
of Zegdi and colleagues1 on our
article entitled ‘‘Surgical aortic valve
replacement after percutaneous aortic
valve implantation: what have we
learned?’’2 The authors raised several
important questions about transcath-
eter heart valve (THV) size selection
according to the aortic annular diame-
ter and the issue of oversizing. In the
case reported a 23-mm balloon ex-
pandable Cribier–Edwards THV had
been selected for an aortic annulus
measured to 20 mm by using echocar-
diographic analysis (2 mm of oversiz-
ing), which was in agreement with the
Edwards company’s recommenda-
tions. After THV implantation, it
clearly appeared that the THV size
was too small, explaining the subse-
quent severe paravalvular leak leading
to surgical valve replacement.
Retrospectively, it seems that
the transthoracic echocardiographic
(TTE) and transesophageal echocar-
diographic (TEE) measurements defi-
nitely underestimated the annular
diameter. A 26-mm THV size should
have been implanted in this patient,
as in any similarly tall male patient.
The lack of annular ring in the stented
THV device might explain the differ-
ence with the bioprosthesis size (23
mm) surgically implanted in this pa-
tient. The accuracy of annular size
echocardiographic measurement is
a technical issue, which has been
solved thereafter. This patient was
our second case included in the first
multicenter European Registry of En-
dovascular Implantation of Valves in
Letters to the EditorReply to the Editor:
We appreciate the comments by
Vedamurthy and associates1 on our
meta-analysis.2 The standardized
mean difference (SMD) is used as
a summary statistic in meta-analyses
when the studies all assess the same
outcome but measure it in a variety
of ways (eg, all studies measure de-
pression, but they use different psy-
chometric scales).3 Vedamurthy and
colleagues stated that there were
some errors in the calculation of the
summary estimate: the units for aortic
valve area (AVA) and peak aortic jet
velocity (PAJV) had been mixed in
the calculations. Similar summary esti-
mates, however, can be commonly
found in published meta-analyses. In
a meta-analysis of negative pressure
wound therapy,4 for instance, a changeThe Journain wound area per day (in square cen-
timeters), a change in wound area until
surgical closure (in square centime-
ters), and a relative change in wound
area until surgical closure or hospital
discharge (in percentages) were com-
bined by using the SMD method.
Although Vedamurthy and associates1
projected the AVA and PAJV change
per year by using the baseline values
and percentage change data expressed
in the original articles, precise calcula-
tion methods were not mentioned.
Was the mean of the absolute change
in the AVA or PAJV calculated by
multiplying the mean of the baseline
value by the mean of the percentage
change? It is mathematically obvious,
however, that the mean of the absolute
change is not equal to the product of
the mean of the baseline value by the
mean of the percentage change. Fur-
thermore, how was the standard devia-
tion (SD) of the change in the AVA or
PAJV? The SD of the absolute change
also cannot be equal to the product of
the mean of the baseline value by the
SD of the percentage change. We do
not have the slightest doubt that the
SMD method using the absolute and
percentage changes themselves ex-
pressed in the original article is better
than the simple mean difference
method using the absolute changes
that are complexly calculated by
authors of a meta-analysis. However,
we would like to know how Vedamur-
thy and associates calculated the mean
or SD of the absolute change.
Hisato Takagi, MD, PhD
Takuya Umemoto, MD, PhD
Department of Cardiovascular
Surgery
Shizuoka Medical Center
Shizuoka, Japan
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